Publications:

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research

Catalanotti, Federica F; Solit, David B DB; Pulitzer, Melissa P MP; Berger, Michael F MF; Scott, Sasinya N SN; Iyriboz, Tunc T; Lacouture, Mario E ME; Panageas, Katherine S KS; Wolchok, Jedd D JD; Carvajal, Richard D RD; Schwartz, Gary K GK; Rosen, Neal N; Chapman, Paul B PB

Publication Date: 2013-04-15

Variant appearance in text: RB1: E79K

PubMed Link: 23444215

Variant Present in the following documents:

• Main text

View BVdb publication page